Pharmasset News

The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, dayA's sales outstanding, dayA's outstanding inventory, cash and short-term investments per share and total common shares outstanding.

SUMMARY: Pharmasset, Inc. last week announced that its development partner Roche will continue enrolling participants in a Phase 2b study of the experimental nucleoside analog hepatitis C virus polymerase inhibitor RG7128 plus pegylated interferon/ribavirin , following a favorable review of safety data.

A control arm with Pegasys and ribavirin for 48 weeks. Patients randomized to the 24-week regimen will discontinue all treatment at week 24 if they have achieved a rapid virological response, defined as serum HCV RNA below the limit of detection at week 4, a strategy known as "RVR-guided" treatment.

InterMune, Inc. and Pharmasset, Inc. today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1 study of two direct-acting antiviral compounds administered without interferon or ribavirin for the treatment of patients chronically infected with the hepatitis C virus .

BUYINS.NET, www.buyins.net, has reviewed the NYSE, NASDAQ, BX, CHX and NSX Daily Short Volume Report for Thursday, October 8th, 2009 and come to the following statistical conclusions.

Pharmasset, Inc. recently announced that it has chosen its experimental hepatitis C virus polymerase inhibitor PSI-352879 -- a purine nucleotide analog -- as a candidate for further preclinical development.

Pharmasset selects PSI-879 as nucleotide analogue inhibitor of hepatitis C for preclinical development Published in M2Europharma on Tuesday, 06 October 2009 at 14:46 GMT 6 October 2009 - US clinical-stage pharmaceutical company Pharmasset Inc said today it has nominated PSI-352879 as a second development candidate from two series of purine ...

Analyst Report ) with a 'Neutral' rating and $2 price target. Our neutral rating stems from the very early-stage nature of the company's pipeline -- leading candidate FV-100 is currently in phase II testing -- and the potential dilution risk coming from cash-raising activities later in 2009 or in 2010.

Pharmasset, Inc. announces management will present at the Robert W. Baird & Co. Health Care Conference, Morgan Stanley Unplugged Global Healthcare Conference and the UBS Global Life Sciences Conference in New York, NY and the ThinkEquity G6 Conference in San Francisco, CA.

Pharmasset, Inc. reported today positive preliminary results from its phase I clinical trial of PSI-7851 for the treatment of hepatitis C . PSI-7851 is a second generation nucleotide polymerase inhibitor of HCV.

Pharmasset, Inc. announced today the nomination of PSI-352938 as a lead development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus infection.

Pharmasset selects PSI-938 as new nucleotide analogue inhibitor of hepatitis C for preclinical development M2Europharma on Tuesday, 07 July 2009 at 14:34 GMT 7 July 2009 - US clinical-stage pharmaceutical company Pharmasset Inc said today it had nominated PSI-352938 as a lead development candidate from two series of purine analogues for the ...

Two companies recently announced that their experimental hepatitis C therapies had moved further along in clinical trials.

BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for June 17, 2009.

Pharmasset, Inc. announced today that it had completed the single ascending dose study and begun dosing in a multiple ascending dose trial with PSI-7851, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection.

Financial Results Revenues were $1.9 million during the quarter ended March 31, 2009 compared to $0.5 million for the quarter ended March 31, 2008 and reflect the receipt of $1.4 million of research and development payments and the amortization of up-front and subsequent collaborative and license payments received from Roche.